Myelotoxicity from chemotherapy

被引：56
作者：
Daniel, D
Crawford, J
机构：
[1] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med Hematol Oncol, Durham, NC 27710 USA
来源：
SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 01期
关键词：
D O I：
10.1053/j.seminoncol.2005.11.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain. © 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码：74 / 85
页数：12
相关论文
共 76 条
[1]   Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression [J].
Acs, G ;
Zhang, PJ ;
McGrath, CM ;
Acs, P ;
McBroom, J ;
Mohyeldin, A ;
Liu, SZ ;
Lu, HS ;
Verma, A .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1789-1806
[2]  
[Anonymous], P AM SOC CLIN ONCOLO
[3]   Expression of erythropoietin receptor splice variants in human cancer [J].
Arcasoy, MO ;
Jiang, XH ;
Haroon, ZA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 307 (04) :999-1007
[4]   Functional significance of erythropoietin receptor expression in breast cancer [J].
Arcasoy, MO ;
Amin, K ;
Karayal, AF ;
Chou, SC ;
Raleigh, JA ;
Varia, MA ;
Haroon, ZA .
LABORATORY INVESTIGATION, 2002, 82 (07) :911-918
[5]  
ASHLEY J, 2004, J SUPPORT ONCOL S2, V2, P66
[6]   Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].
Auerbach, M ;
Ballard, H ;
Trout, JR ;
McIlwain, M ;
Ackerman, A ;
Bahrain, H ;
Balan, S ;
Barker, L ;
Rana, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307
[7]   Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy [J].
Barrett-Lee, PJ ;
Bailey, NP ;
O'Brien, MER ;
Wager, E .
BRITISH JOURNAL OF CANCER, 2000, 82 (01) :93-97
[8]   Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer [J].
Basser, RL ;
Rasko, JEJ ;
Clarke, K ;
Cebon, J ;
Green, MD ;
Hussein, S ;
Alt, C ;
Menchaca, D ;
Tomita, D ;
Marty, J ;
Fox, RM ;
Begley, CG .
LANCET, 1996, 348 (9037) :1279-1281
[9]  
Blackwell S., 1994, FILGRASTIM R METHUG, P103
[10]   A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy [J].
Blay, JY ;
La Cesne, A ;
Mermet, C ;
Maugard, C ;
Ravaud, A ;
Chevreau, C ;
Sebban, C ;
Guastalla, JP ;
Biron, P ;
Ray-Coquard, I .
BLOOD, 1998, 92 (02) :405-410
12345678